KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Thermo Fisher Scientific (TMO) Receivables - Net (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Receivables - Net readings, the most recent being $9.2 billion for Q1 2026.

  • On a quarterly basis, Receivables - Net rose 8.86% to $9.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $9.2 billion, a 8.86% increase, with the full-year FY2025 number at $8.9 billion, up 8.66% from a year prior.
  • Receivables - Net hit $9.2 billion in Q1 2026 for Thermo Fisher Scientific, up from $8.9 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $9.2 billion in Q1 2026 to a low of $7.7 billion in Q4 2022.
  • Median Receivables - Net over the past 5 years was $8.2 billion (2024), compared with a mean of $8.3 billion.
  • Biggest five-year swings in Receivables - Net: soared 42.04% in 2022 and later fell 1.37% in 2024.
  • Thermo Fisher Scientific's Receivables - Net stood at $8.1 billion in 2022, then increased by 1.31% to $8.2 billion in 2023, then dropped by 0.36% to $8.2 billion in 2024, then rose by 8.66% to $8.9 billion in 2025, then rose by 3.42% to $9.2 billion in 2026.
  • The last three reported values for Receivables - Net were $9.2 billion (Q1 2026), $8.9 billion (Q4 2025), and $8.9 billion (Q3 2025) per Business Quant data.